# Omixon Biocomputing

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/omixon-biocomputing

- Industry: Software
- Headquarters: Budapest, Hungary
- Website: www.omixon.com
- Total disclosed funding: $1.7M
- Latest round: Series C (Jan 5, 2017)
- Investors on record: 2

## About

Omixon Biocomputing Ltd. is a specialized provider of molecular diagnostics focused on HLA genotyping through Next Generation Sequencing technologies, offering innovative solutions to improve transplant outcomes.Founded in 2011 and headquartered in Budapest, Hungary, Omixon Biocomputing Ltd. specializes in molecular diagnostics. The company has completed four investment deals, with the most recent funding round being a Series A of HUF 400.000 mn led by Euroventures on January 5, 2017. The company is led by CEO Attila Bérces, who has a history in the biotechnology field.Omixon Biocomputing Ltd. specializes in molecular diagnostics with a focus on HLA (Human Leukocyte Antigen) genotyping through Next Generation Sequencing (NGS) technologies. Their core product offerings include the Holotype HLA™, an NGS Assay and Software product designed for clinical use on Illumina® sequencers, and the NanoTYPE MONO™ & MONOall™ kits, which are tailored for single locus testing. Additionally, the HoloGRAFT ONE™ test is utilized in research applications to quantify donor-derived cell-free DNA in transplant recipients. These products cater primarily to histocompatibility laboratories and medical institutions, with a customer base that includes transplant centers and research facilities across North America, Europe, and select regions in Asia. By providing innovative solutions for HLA typing, Omixon aims to improve transplant outcomes and enhance patient care.Omixon's revenue model is structured around the sale of specialized products and services, primarily targeting B2B transactions with healthcare providers and research institutions. Their offerings include the flagship Holotype HLA™ and the NanoTYPE kits, which are available in various formats to meet specific needs. Customers engage in direct purchases, with products offered as Research Use Only (RUO) kits and clinical diagnostic solutions. The company reported a revenue of HUF 4,495,332.20 in 2023, with an EBITDA of HUF 557,208.40 for the same year.Omixon Biocomputing Ltd. is focusing on the development of new products aimed at enhancing their diagnostic offerings, with details on specific launch dates to be announced. The company plans to expand into new markets, specifically targeting regions in Asia and North America by 2025. The recent Series A funding of HUF 400.000 mn will be utilized to support these initiatives, including product development and market expansion strategies.

## Funding rounds

- Series C, Jan 5, 2017 — FastVentures
- Series B, Feb 1, 2015 — FastVentures, Euroventures
- Series A, May 30, 2012, $1.7M — FastVentures, Euroventures

## Investors

- FastVentures (https://capitalatlas.ai/funds/fastventures) — Series A, Series B, Series C
- Euroventures (https://capitalatlas.ai/funds/euroventures) — Series A, Series B